PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT05234307 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Adenosine A2B Receptor Antagonist PBF-1129
PROCEDURE: Biospecimen Collection
BIOLOGICAL: Nivolumab

Sponsor

Dwight Owen

Collaborators

[object Object]